ZymoGenetics to Present at American Society of Hematology Annual Meeting
Sunday, December 9, 2007 -0-
Time: 9:00 a.m.-8:00 p.m. ET Room: Hall B3 and B4 in the Georgia World Congress Center Poster Board #: 767 Title: Recombinant Interleukin-21 Plus Rituximab: Clinical Activity in a Phase 1, Dose-Finding Trial in Relapsed Low-Grade B Cell Lymphoma. Session Name: New Agents and Treatment Approaches in Non-Hodgkins Lymphoma
Monday, December 10, 2007 -0-
Time: 10:30 a.m.-7:00 p.m. ET Room: Hall B3 and B4 in the Georgia World Congress Center Poster Board #: 375 Title: Recombinant Thrombin Has a Superior Immunogenicity Profile Compared with Bovine Thrombin in a Well-Controlled, Randomized, Double-Blind, Phase 3 Study of Topically Applied Thrombins in Four Surgical Settings. (Encore presentation) Session Name: Coagulation-Based Therapies and Assays
ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The Company is developing a diverse pipeline of product candidates that are moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune and viral diseases and cancer. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.
Investor and Media Relations:
Susan W. Specht, MBA
Director, Corporate Communications
Posted: December 2007